Osteoarthritis (OA) is the most prevalent chronic joint disease and a prominent cause of pain, distress and disability1. The burden of OA to patients is often underestimated2 and the health economic burden is growing with increased life expectancy and risk factors such as obesity and additional comorbidities1.
Current pharmacological treatments for OA are focussed on symptomatic analgesia. Guideline changes have downgraded the use of paracetamol and opioids and highlighted the need for personalised pain management3–5. There are, however, emerging therapies for OA pain control which could impact the burden of OA in the future1.
Developed by EPG Health for Medthority. This content has been developed independently of the sponsors Pfizer and Lilly, who have had no editorial input into the content. EPG Health received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.